Genetic and physiological data implicating the new human gene G72 and the gene for <scp>d</scp> -amino acid oxidase in schizophrenia

  • Ilya Chumakov
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Marta Blumenfeld
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Oxana Guerassimenko
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Laurent Cavarec
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Marta Palicio
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Hadi Abderrahim
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Lydie Bougueleret
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Caroline Barry
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Hiroaki Tanaka
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Philippe La Rosa
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Anne Puech
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Nadia Tahri
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Annick Cohen-Akenine
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Sylvain Delabrosse
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Sébastien Lissarrague
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Françoise-Pascaline Picard
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Karelle Maurice
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Laurent Essioux
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Philippe Millasseau
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Pascale Grel
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Virginie Debailleul
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Anne-Marie Simon
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Dominique Caterina
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Isabelle Dufaure
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Kattayoun Malekzadeh
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Maria Belova
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Jian-Jian Luan
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Michel Bouillot
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Jean-Luc Sambucy
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Gwenael Primas
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Martial Saumier
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Nadia Boubkiri
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Sandrine Martin-Saumier
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Myriam Nasroune
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Hélène Peixoto
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Arnaud Delaye
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Virginie Pinchot
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Mariam Bastucci
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Sophie Guillou
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Magali Chevillon
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Ricardo Sainz-Fuertes
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Said Meguenni
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Joan Aurich-Costa
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Dorra Cherif
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Anne Gimalac
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Cornelia Van Duijn
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Denis Gauvreau
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Gail Ouelette
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Isabel Fortier
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • John Realson
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Tatiana Sherbatich
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Nadejda Riazanskaia
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Evgeny Rogaev
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Peter Raeymaekers
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Jeroen Aerssens
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Frank Konings
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Walter Luyten
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Fabio Macciardi
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Pak C. Sham
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Richard E. Straub
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Daniel R. Weinberger
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Nadine Cohen
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
  • Daniel Cohen
    Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892

抄録

<jats:p> A map of 191 single-nucleotide polymorphism (SNPs) was built across a 5-Mb segment from chromosome 13q34 that has been genetically linked to schizophrenia. DNA from 213 schizophrenic patients and 241 normal individuals from Canada were genotyped with this marker set. Two 1,400- and 65-kb regions contained markers associated with the disease. Two markers from the 65-kb region were also found to be associated to schizophrenia in a Russian sample. Two overlapping genes G72 and G30 transcribed in brain were experimentally annotated in this 65-kb region. Transfection experiments point to the existence of a 153-aa protein coded by the G72 gene. This protein is rapidly evolving in primates, is localized to endoplasmic reticulum/Golgi in transfected cells, is able to form multimers and specifically binds to carbohydrates. Yeast two-hybrid experiments with the G72 protein identified the enzyme <jats:sc>d</jats:sc> -amino acid oxidase (DAAO) as an interacting partner. DAAO is expressed in human brain where it oxidizes <jats:sc>d</jats:sc> -serine, a potent activator of <jats:italic>N</jats:italic> -methyl-D-aspartate type glutamate receptor. The interaction between G72 and DAAO was confirmed <jats:italic>in vitro</jats:italic> and resulted in activation of DAAO. Four SNP markers from DAAO were found to be associated with schizophrenia in the Canadian samples. Logistic regression revealed genetic interaction between associated SNPs in vicinity of two genes. The association of both DAAO and a new gene G72 from 13q34 with schizophrenia together with activation of DAAO activity by a G72 protein product points to the involvement of this <jats:italic>N</jats:italic> -methyl- <jats:sc>d</jats:sc> -aspartate receptor regulation pathway in schizophrenia. </jats:p>

収録刊行物

被引用文献 (50)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ